MetLife Investment Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

MetLife Investment Management’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,520	Closed	-$172K	–	2436
2019 Q2	$172K	Hold	12,520	–	–	﹤0.01%	2119
2019 Q1	$216K	Hold	12,520	–	–	﹤0.01%	1939
2018 Q4	$160K	Hold	12,520	–	–	﹤0.01%	2032
2018 Q3	$203K	Buy	+12,520	New	+$179K	﹤0.01%	2067

Other funds holding OXFD

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

MetLife Investment Management's OXFD Position: Q3 2019 in Review

MetLife Investment Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q3 2019, closing a stake of 12,520 shares — an estimated $172K sold.

MetLife Investment Management first reported a position in OXFD in Q3 2018 and held it in 4 quarters. The position peaked at $216K in Q1 2019. 73 funds tracked by Wall St. Rank hold OXFD as of Q3 2019.

MetLife Investment Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q3 2019 after selling out during the quarter.
MetLife Investment Management sold 12,520 Oxford Immunotec Global PLC Ordinary Shares shares in Q3 2019, an estimated $172K.
MetLife Investment Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q3 2018 and held it in 4 quarters.
MetLife Investment Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $216K in Q1 2019.
73 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q3 2019.

Based on MetLife Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.